Milestone Pharmaceuticals (MIST) News
NASDAQ: MISTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
0.765+0.0529 (+7.43%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
MIST news summary
We found 3 recent headlines mentioning Milestone Pharmaceuticals (MIST): 2 in the past week and 2 in the past 30 days, most often from Nasdaq, GlobeNewswire. MIST is making an outsized move today, up 7.43% at $0.765, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Sagimet Reports Sustained Acne Improvements With Denifanstat Through 52 Weeks", was published by Nasdaq on Oct 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Milestone Pharmaceuticals headlines
- Sagimet Reports Sustained Acne Improvements With Denifanstat Through 52 Weeks(RTTNews) - Sagimet Biosciences Inc. (SGMT) announced positive 52-week results from a Phase 3 open-label extension study of denifanstat in patients with moderate-to-severe acne vulgaris. The data,…NasdaqMIST, BRK.B
- Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical TrialDutch Cardiovascular Investigator Network (WCN) Leads European Enrollment in Phase 3 Study Evaluating Etripamil Nasal Spray for AFib-RVR Dutch Cardiovascular Investigator Network (WCN) Leads European…GlobeNewswire
- Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals(RTTNews) - This week's biotech roundup saw a flurry of FDA and EU approvals across neurology, oncology, cardiology, and rare diseases, alongside new partnerships, trial readouts, and restructuring…NasdaqAPVO, ASND, AZN, BIIB